Skip to main content

Table 1 Patient characteristics

From: FOLFIRI plus panitumumab in the treatment of wild-type KRAS and wild-type NRAS metastatic colorectal cancer

Characteristics n Percentile (%)
Sex Female 29 45.3
Male 35 54.7
Pathology Adenocarcinoma 61 95.3
Mucinous 3 4.7
Grade I 4 6.3
II 57 89.1
III 3 4.7
KRAS Wild 64 100
NRAS Wild 64 100
Biopsy location Primary tumour 61 95.3
Metastasis 3 4.7
Metastasis diagnosed Synchronous 45 70.3
Metachronous 19 29.7
Right colon Total 8 12.5
Ascending colon 5 7.8
Transverse colon 3 4.7
Left colon Total 56 87.5
Rectum 21 32.8
Sigmoid colon 33 51.6
Descending colon 2 3.1
Metastasis location Liver 46 71.9
Lung 7 10.9
Peritoneum 4 6.3
Bone 4 6.3
Remote lymph node 3 4.7
Metastasectomy Yes 17 26.5
No 47 73.5
Second treatment Yes 40 62.5
No 24 37.5
Progression Yes 50 78.1
No 14 21.9
Death Yes 33 51.5
No 31 48.5